AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 38384801
Drug: UV1 vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UV1 vaccination in combination with pembrolizumab
Trial: 38384801
Drug: Pembrolizumab as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab as a single agent
Trial: 38385243
Drug: Chlorambucil plus
RxNorm normalized name: Chlorambucil
DrugBank: Chlorambucil (DB00291)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorambucil plus subcutaneous rituximab induction and maintenance
Trial: 38385243
Drug: Subcutaneous rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous rituximab maintenance
Trial: 38385566
Drug: mRNA-1345 (12.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA-1345 (12.5, 25, 50, 100, or 200 µg)
Trial: 38385566
Drug: mRNA-1345 (first
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA-1345 (first injection)
Trial: 38385587
Drug: Fenofibrate (145
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibrate (145 mg tablet daily or on alternate days for those with impaired renal function)
Trial: 38386178
Drug: guselkumab 100
RxNorm normalized name: guselkumab 100 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: guselkumab 100 mg every 8 weeks (Q8W)
Trial: 38386266
Drug: Preoperative 1
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative 1 mg dexamethasone suppression test
Trial: 38386376
Drug: Availability of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Availability of information on diagnosis, current medication, test results, and risk scores
Trial: 38386434
Drug: Community-Derived Open-Source
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-Derived Open-Source Automated Insulin Delivery Loop System
Trial: 38386438
Drug: Insulin Glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin Glargine 300 U/mL
Trial: 38386505
Drug: Single intra-articular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intra-articular injection of GMP manufactured stromal vascular fraction (SVF)
Trial: 38386949
Drug: Zagotenemab 1,400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zagotenemab 1,400 mg
Trial: 38386949
Drug: Zagotenemab 5,600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zagotenemab 5,600 mg
Trial: 38386978
Drug: rilzabrutinib 400
RxNorm normalized name: Rilzabrutinib
DrugBank: Rilzabrutinib (DB17709)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rilzabrutinib 400 mg twice daily
Trial: 38387470
Drug: Hepatitis E
RxNorm normalized name: hepatitis E vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis E vaccine (three doses administered intramuscularly at month 0, month 1, and month 6)
Trial: 38387470
Drug: Placebo (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (three doses administered intramuscularly at month 0, month 1, and month 6)
Trial: 38387597
Drug: 38% silver
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 38% silver diamine fluoride (SDF) treatment applied once per week for 3 weeks
Trial: 38387597
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment applied once per week for 3 weeks
Trial: 38387978
Drug: Data collection
RxNorm normalized name: NO DATA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Data collection from ICU treatment for specific aspects of msTBI care.
Trial: 38388017
Drug: Cooled radiofrequency
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cooled radiofrequency (RF) treatment
Trial: 38388017
Drug: Conventional radiofrequency
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional radiofrequency (RF) treatment
Trial: 38388017
Drug: Cooled RF
RxNorm normalized name: Aminosyn-RF 5.2 %, Sulfite-Free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cooled RF treatment in PPSP
Trial: 38388017
Drug: Conventional RF
RxNorm normalized name: Aminosyn-RF 5.2 %, Sulfite-Free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional RF treatment in PPSP
Trial: 38388017
Drug: Cooled RF
RxNorm normalized name: Aminosyn-RF 5.2 %, Sulfite-Free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cooled RF treatment in OA
Trial: 38388017
Drug: Conventional RF
RxNorm normalized name: Aminosyn-RF 5.2 %, Sulfite-Free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional RF treatment in OA
Trial: 38388022
Drug: Smartphone game
RxNorm normalized name: sulfur
DrugBank: Octasulfur (DB09353)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Smartphone game intervention for HIV prevention; details on dosage and duration not available.
Trial: 38388236
Drug: Booster shot
RxNorm normalized name: ChoreMate One-Shot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster shot with Sabin inactivated poliomyelitis vaccine
Trial: 38388646
Drug: Subcutaneous cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subcutaneous cytarabine (100 mg/m2 for 5 days) administered in 35-day cycles for 12 total cycles
Trial: 38388986
Drug: RBP-7000 (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RBP-7000 (180 mg monthly injections)
Trial: 38389078
Drug: Atorvastatin 40
RxNorm normalized name: atorvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 40 mg once daily for 28 days (group A)
Trial: 38390395
Drug: hyperbaric spinal
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hyperbaric spinal bupivacaine 0.5%, 1.3 ml (0.65 mg)
Trial: 38390815
Drug: Insulin resistance
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin resistance (assessed by the insulin sensitivity index)
Trial: 38391202
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy using azacitidine and nivolumab (Aza/Nivo)
Trial: 38391283
Drug: omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: omega-3 fatty acid treatment
Trial: 38391311
Drug: Quantitative US
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quantitative US (QUS) radiomics data obtained after the 1st week of radiation therapy (RT)
Trial: 38391311
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy (RT) with a total dose of 70 Gy in 33-35 fractions over 6-7 weeks
Trial: 38393328
Drug: Benralizumab (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benralizumab (30 mg)
Trial: 38393676
Drug: Aspirin and
RxNorm normalized name: Aspirin and Caffeine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin and clopidogrel or ticagrelor for 5 days
Trial: 39284337
Drug: Belzutifan 120
RxNorm normalized name: BELZUTIFAN
DrugBank: Belzutifan (DB15463)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Belzutifan 120 mg once daily
Trial: 38394048
Drug: Topical coconut-derived
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical coconut-derived isosorbide diesters, dosage and duration not specified
Trial: 38394048
Drug: Topical sunflower
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical sunflower seed oil-derived isosorbide diesters, dosage and duration not specified
Trial: 38394048
Drug: Vehicle control,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle control, dosage and duration not specified
Trial: 38394113
Drug: Daily notification
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily notification prompts for physical activity (PA)
Trial: 38394387
Drug: Direct oral
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct oral anticoagulants (DOAC) treatment with measurement of DOAC levels
Trial: 38395824
Drug: SRP with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRP with systemic antibiotic administration (spiramycin and metronidazole)
Trial: 38395969
Drug: nDC treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nDC treatment
Trial: 38396126
Drug: Supplementation with
RxNorm normalized name: Similac For Supplementation with Iron Powder for Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplementation with 90 mg vitamin C, 30 mg α-tocopherol (vitamin E), 18 mg vitamin B
Trial: 38396134
Drug: Carboplatin administration
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin administration before sonication
Trial: 38398474
Drug: Mechanical bowel
RxNorm normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mechanical bowel preparation and oral antibiotics
Trial: 38398474
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no mechanical bowel preparation and oral antibiotics)
Trial: 38398703
Drug: Chronic, latent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic, latent toxoplasmosis treatment
Trial: 38400193
Drug: Ad26.ZEBOV and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad26.ZEBOV and MVA-BN-Filo vaccines
Trial: 38400780
Drug: ONC201 administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ONC201 administered D1D2 (twice-weekly)
Trial: 38400780
Drug: ONC201 administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ONC201 administered once-weekly (D1)
Trial: 38400919
Drug: Caffeine gum
RxNorm normalized name: caffeine Chewing Gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine gum (300 mg)
Trial: 38401036
Drug: L-Glutamine (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Glutamine (0.1 g/kg twice daily, 0.3 g/kg twice daily, 0.6 g/kg once daily)
Trial: 38401036
Drug: L-Glutamine (multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Glutamine (multiple doses over 3 weeks)
Trial: 38401036
Drug: L-Glutamine (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Glutamine (oral therapy)
Trial: 38401647
Drug: NOAC monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NOAC monotherapy
Trial: 38401647
Drug: NOAC plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NOAC plus clopidogrel combination therapy
Trial: 38401649
Drug: Early UFH
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early UFH administration (iv. bolus of 100 units/kg UFH)
Trial: 38401649
Drug: Late UFH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late UFH administration (iv. bolus of 100 units/kg UFH)
Trial: 38401789
Drug: Group cognitive
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group cognitive behavioral therapy intervention
Trial: 38402303
Drug: FluMos-v1 (mosaic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FluMos-v1 (mosaic influenza nanoparticle vaccine)
Trial: 38402361
Drug: Extensive ICU
RxNorm normalized name: SET,INFUSION,EXTENSION ICU#B33024
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extensive ICU treatment (invasive ventilation for > 24 hours, continuous renal replacement therapy, or both)
Trial: 38402708
Drug: Intermittent low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent low glycemic index therapy (LGIT)
Trial: 38402708
Drug: Daily low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily low glycemic index therapy (LGIT)
Trial: 38402886
Drug: Sunitinib (37.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib (37.5 mg per day)
Trial: 38403186
Drug: Bilateral transcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral transcutaneous noninvasive electromagnetic phrenic nerve stimulation (NEPNS) for 15 minutes, twice daily (bid).
Trial: 38403793
Drug: Cotadutide (200-μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cotadutide (200-μg dose)
Trial: 38403865
Drug: AZD7442 (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD7442 (600 mg intramuscular, 300 mg tixagevimab/300 mg cilgavimab)
Trial: 38403887
Drug: Multi-component intervention
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-component intervention including initiation of antiretroviral therapy (ART) during admission, strengths-based case management, and naltrexone
Trial: 38404532
Drug: Educational intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Educational intervention on oral health
Trial: 38405151
Drug: Fludrocortisone (lower
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludrocortisone (lower doses)
Trial: 38405151
Drug: Stress dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stress dosing
Trial: 38406813
Drug: THP regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THP regimen (docetaxel 75 mg/m2, trastuzumab biosimilar TQB211 8 mg/kg first cycle, 6 mg/kg maintenance, pertuzumab biosimilar TQB2440 or pertuzumab 840 mg first cycle, 420 mg maintenance)
Trial: 38407317
Drug: Tuvusertib (M1774)
RxNorm normalized name: Tuvusertib
DrugBank: Tuvusertib (DB18790)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tuvusertib (M1774) 180 mg QD (once daily), 2 weeks on/1 week off treatment
Trial: 38407372
Drug: Non-oral route
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-oral route of medication administration
Trial: 38407372
Drug: Modification of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modification of solid medications (SMs)
Trial: 38407372
Drug: Modified medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified medication administration before specialist consultation
Trial: 38407372
Drug: Avoidance of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avoidance of whole SMs administration
Trial: 38407508
Drug: Parsaclisib (5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parsaclisib (5, 10, 15, 20, 30, and 45 mg once daily)
Trial: 38407601
Drug: Zosuquidar (Zos)
RxNorm normalized name: Dynashield ZO
DrugBank: Zosuquidar (DB06191)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zosuquidar (Zos) as a 72-h continuous intravenous infusion with chemotherapy (daunorubicin and cytarabine)
Trial: 38407601
Drug: Zosuquidar (Zos)
RxNorm normalized name: Dynashield ZO
DrugBank: Zosuquidar (DB06191)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zosuquidar (Zos) as a 72-h continuous intravenous infusion
Trial: 38407859
Drug: Viaskin milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viaskin milk 300 μg
Trial: 38407859
Drug: Viaskin milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viaskin milk 300 μg (2 to 11 years age group)
Trial: 38407859
Drug: Viaskin milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viaskin milk (all doses)
Trial: 38407859
Drug: Viaskin milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viaskin milk 500 μg
Trial: 38407974
Drug: DNAase (0.1%)
RxNorm normalized name: Recombinant deoxyribonuclease (DNAse)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DNAase (0.1%) eye drops four times daily for 8 weeks
Trial: 38408060
Drug: Low-dose naltrexone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose naltrexone (4.5mg)
Trial: 38408215
Drug: PrEP (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PrEP (oral pre-exposure prophylaxis)
Trial: 38408443
Drug: Topical Palmitoylethanolamide
RxNorm normalized name: Palmitoylethanolamide
DrugBank: Palmidrol (DB14043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Palmitoylethanolamide (Levagen+) applied twice daily for 4 weeks
Trial: 38408443
Drug: Standard moisturiser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard moisturiser (comparator) applied twice daily for 4 weeks
Trial: 38408457
Drug: Dengue monoclonal
RxNorm normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dengue monoclonal antibody (1 mg/kg, 3 mg/kg, 7 mg/kg, 12 mg/kg)
Trial: 38408457
Drug: Dengue monoclonal
RxNorm normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dengue monoclonal antibody (1 mg/kg)
Trial: 38408457
Drug: Dengue monoclonal
RxNorm normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dengue monoclonal antibody (3 mg/kg)
Trial: 38408457
Drug: Dengue monoclonal
RxNorm normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dengue monoclonal antibody (7 mg/kg)
Trial: 38408457
Drug: Dengue monoclonal
RxNorm normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dengue monoclonal antibody (12 mg/kg)
Trial: 38408457
Drug: Dengue monoclonal
RxNorm normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dengue monoclonal antibody
Trial: 38408729
Drug: Daily consumption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily consumption of a beverage sweetened with 25% of the ADI of stevia for 4 weeks
Trial: 38408729
Drug: Daily consumption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily consumption of a beverage sweetened with 30 g of sucrose for 4 weeks
Trial: 38408999
Drug: Zilovertamab in
RxNorm normalized name: Zilovertamab
DrugBank: Zilovertamab (DB18403)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zilovertamab in combination with paclitaxel
Trial: 38409060
Drug: Somatosensory discrimination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatosensory discrimination therapy
Trial: 38409060
Drug: Upper limb
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Upper limb motor therapy
Trial: 38409089
Drug: Combination nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combination nicotine replacement therapy (NRT) gum + NRT patch
Trial: 38409129
Drug: Body Awareness
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Body Awareness Therapy (BAT) + Pulmonary Rehabilitation (PR)
Trial: 38409332
Drug: Bone marrow-derived
RxNorm normalized name: Allogeneic human bone marrow-derived mpc
DrugBank: Rexlemestrocel-L (DB17606)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone marrow-derived mesenchymal stromal cell (MSC) infusion
Trial: 38410109
Drug: CC-3 bispecific
RxNorm normalized name: B-CELL MATURATION ANTIGEN (BCMA) CLUSTER OF DIFFERENTIATION 3 (CD3) BISPECIFIC MONOCLONAL ANTIBODY (MAB) ANTI-BCMA/ANTI-CD3 BISPECIFIC MAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-3 bispecific CD276xCD3 antibody, starting dose of 50 µg, with potential increases up to 800 µg depending on safety review.
Trial: 38410109
Drug: CC-3 bispecific
RxNorm normalized name: B-CELL MATURATION ANTIGEN (BCMA) CLUSTER OF DIFFERENTIATION 3 (CD3) BISPECIFIC MONOCLONAL ANTIBODY (MAB) ANTI-BCMA/ANTI-CD3 BISPECIFIC MAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-3 bispecific CD276xCD3 antibody at maximum tolerated dose (MTD) after determination, additional 14 patients.
Trial: 38410116
Drug: ELENAGEN (plasmid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ELENAGEN (plasmid encoding p62/SQSTM1) in combination with gemcitabine (GEM) 1000 mg/m²
Trial: 38410116
Drug: Gemcitabine (GEM)
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine (GEM) 1000 mg/m²
Trial: 38410567
Drug: S-HITHOC (cytoreductive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-HITHOC (cytoreductive surgery combined with hyperthermic intrathoracic chemotherapy)
Trial: 38410608
Drug: Consolidative hypofractionated
RxNorm normalized name: BAG,LEG LARGE CONSOLIDATED #0932
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consolidative hypofractionated radiation therapy (hfRT) using stereotactic body radiotherapy (SBRT) starting from 6.5 Gy ×2 fractions and escalating to 10 Gy ×2 fractions, delivered 1 to 2 months after dCRT and concurrently with durvalumab.
Trial: 38410608
Drug: Adjuvant anti-PD-L1
RxNorm normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Adjuvant anti-PD-L1 therapy using durvalumab, delivered concurrently with hfRT.
Trial: 38410920
Drug: Immunotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy with durvalumab and tremelimumab